Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Developing an instrument to measure the quality of social work cancer counseling regarding return to work - psychometric properties of the German Quality of Cancer Counseling Questionnaire-Return to Work (QCCQ-W).","authors":"Clara Breidenbach, Sabine Schneider, Marie Rösler, Nicole Ernstmann, Paula Heidkamp, Lina Heier, Kati Hiltrop, Sophie Schellack, Johannes Soff, Johanna Weiss, Christoph Kowalski","doi":"10.1007/s00432-024-06040-6","DOIUrl":"10.1007/s00432-024-06040-6","url":null,"abstract":"<p><strong>Purpose: </strong>Counseling by social workers can be of great relevance supporting cancer survivors with their psychosocial challenges such as returning to work. However, an instrument for assessing the quality between social worker and client in the cancer counseling setting regarding return to work is not yet available. This study was carried out to develop and validate an instrument for this purpose.</p><p><strong>Methods: </strong>A questionnaire was developed in collaboration with cancer counseling experts. Data collection took place in 19 outpatient cancer counseling centers in Germany. Cancer survivors seeking advice regarding their occupational situation were asked to complete the questionnaire 3 months after starting counseling. Exploratory factor analysis (n = 229) and confirmatory factor analysis (n = 216) in two distinct samples, as well as validity and reliability tests, were performed.</p><p><strong>Results: </strong>Exploratory factor analysis suggested a two-component solution. Confirmatory factor analysis confirmed this solution, with a satisfactory model fit (CFI = 0.995, RMSEA = 0.049, SRMSR = 0.036). The components identified included six items with three items each and were termed \"1. relationship building\" and \"2. competent support.\" The components had good internal consistency (Cronbach's α between 0.84 and 0.92) and test-retest reliability (1. r(30) = 0.49, p = 0.005, 2. r(30) = 0.89, p < 0.001). Significant correlations with other constructs measuring satisfaction with counseling and its usefulness indicated moderate to good construct validity (r between 0.36 and 0.77, p < 0.001).</p><p><strong>Conclusion: </strong>The questionnaire developed shows satisfactory psychometric properties. It is an evaluation tool specific for cancer counseling regarding return to, since it will initially be used to evaluate an intensified program for supporting cancer survivors returning to work after treatment. It may also be tested as an instrument for quality assurance and management in general cancer counseling in the future.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"7"},"PeriodicalIF":2.7,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preferences of melanoma patients to accept adjuvant therapy and toxicity - a qualitative substudy of the GerMelaTox-A project.","authors":"Toni Maria Janke, Laura Moysig, Christine Blome, Katharina C Kähler","doi":"10.1007/s00432-024-06014-8","DOIUrl":"10.1007/s00432-024-06014-8","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted treatment and immunotherapy, both adjuvant treatment options, come with a certain toxicity and can cause severe side effects. To date, data about the underlying reasons for patients to accept or reject specific types of adjuvant therapy is scarce. Therefore, this study investigates the motives of melanoma patients for tolerating or rejecting adjuvant therapy and its side effects.</p><p><strong>Methods: </strong>We conducted semi-structured interviews with a subsample of patients to investigate the underlying reasons for treatment decisions in a quantitative treatment-trade off study. Categorisation was conducted using qualitative content analysis.</p><p><strong>Results: </strong>The 17 participants had a mean age of 55.5 years and 12 were female. The final category system covered three clusters. The cluster \"type of therapy and therapy process\" described therapy-related aspects that affect acceptability of adjuvant treatments. Prospect of treatment benefit and side effects were important aspects. Route of administration and physician visits should be convenient. The cluster \"way of living\" described the influence that activities and circumstances of life organisation have on acceptability. Participants wished treatment to affect everyday life as little as possible. Maintaining sufficient quality of life was mentioned to be crucial. The cluster \"emotions and feelings\" described optimism and hope but also mental strain originating from possible treatment options.</p><p><strong>Conclusion: </strong>Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity. The evaluation of potential side effects and prospects of treatment benefit is highly individual. Therefore, it is important to consider personal patient preferences to make appropriate and shared decision-making.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"3"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia.","authors":"Zinaida Stupakova, Iryna Diagil, Ulyana Melnyk, Oksana Karnabeda, Anna Sergeieva","doi":"10.1007/s00432-024-06053-1","DOIUrl":"10.1007/s00432-024-06053-1","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"517"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of robotic-assisted and laparoscopic partial nephrectomy based on the PADUA score and the predictive value of the PADUA score and the Mayo Adhesive Probability score for postoperative complications: a single-center retrospective study.","authors":"Shuo Liu, Bowen Zhang, Bowen Weng, Xiangqiang Liu, Sichuan Hou","doi":"10.1007/s00432-024-06037-1","DOIUrl":"10.1007/s00432-024-06037-1","url":null,"abstract":"<p><strong>Purpose: </strong>This study compared perioperative outcomes of robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN) through the PADUA score as well as assessed the predictive value of the PADUA score and the Mayo Adhesive Probability (MAP) score for postoperative complications.</p><p><strong>Methods: </strong>Totally 196 patients suffering from RAPN or LPN for renal tumors were reviewed retrospectively. Patients were categorized by PADUA score (low-, moderate-, high-complexity) and MAP score (low-, intermediate-, high-grade). Evaluated outcomes included operative time (OT), warm ischemia time (WIT), estimated blood loss (EBL), drainage duration, postoperative length of stay, and absolute change in estimated glomerular filtration rate (eGFR) at three months post-surgery, along with intra- and postoperative complications.</p><p><strong>Results: </strong>RAPN outperformed LPN in the low-complexity group by lowering WIT (P = 0.022) and absolute eGFR change (P = 0.011). For moderate-complexity group, RAPN reduced WIT (P = 0.021), absolute eGFR change (P = 0.027), and postoperative length of stay (P = 0.008). In the high-complexity group, RAPN reduced OT (P = 0.015), WIT (P = 0.023), EBL (P = 0.036), absolute eGFR change (P = 0.024), and postoperative length of stay (P = 0.019). Drainage duration showed no significant differences across groups (P = 0.442, P = 0.327, P = 0.260). RAPN incurred significantly higher total costs than LPN across groups (P < 0.001). ROC analysis suggested PADUA and MAP scores as reliable predictors of postoperative complications in RAPN (AUC = 0.880,0.828) and LPN (AUC = 0.757,0.702).</p><p><strong>Conclusion: </strong>RAPN provides significant advantages over LPN in managing complex renal tumors (PADUA score ≥ 10), significantly in reducing OT, WIT, EBL, and absolute eGFR change at three months post-surgery, while minimizing postoperative stay. The PADUA and MAP scores are valuable in predicting postoperative complication.</p><p><strong>Trial registration number and date of registration: </strong>Retrospectively registered.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"1"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based cancer care: assessing guideline adherence of multidisciplinary tumor board recommendations for breast and colorectal cancer in a non-academic medical center.","authors":"Carl-Stephan Leonhardt, Leopold Lanzenberger, Raphael Puehringer, Ulla Klaiber, Irene Hauser, Oliver Strobel, Gerald Prager, Martin Bodingbauer","doi":"10.1007/s00432-024-06049-x","DOIUrl":"10.1007/s00432-024-06049-x","url":null,"abstract":"<p><strong>Purpose: </strong>Multidisciplinary tumor boards (MTB) are associated with improved outcomes. Yet, most patients in Western countries receive cancer care at non-academic medical centers. Guideline adherence of MTB recommendations in non-academic medical centers as well as factors contributing to non-adherence remain largely unexplored.</p><p><strong>Methods: </strong>This retrospective study followed the STROBE recommendations. All cases discussed at the MTB of the Landesklinikum Baden-Moedling, Austria, were eligible for inclusion. Guideline non-adherence was assessed by two reviewers independently using the AWMF S3 guidelines. Factors associated with guideline non-adherence were investigated using multivariable ordinal regression.</p><p><strong>Results: </strong>In total, 579 patients were included in the final analysis: 486 were female (83.9%) and 93 were male (16.1%), with a median age of 70 years (IQR 60-80). Most had breast cancer (n = 451; 77.9%), while 128 had colorectal cancer (22.1%). Complete adherence to guidelines was observed in 453 patients (78.2%), major deviations in 60 (10.4%), and minor deviations in 66 (11.4%) patients. Non-adherence was primarily due to patient preferences (n = 24; 40.0%), lack of surgical treatment recommendation (n = 24; 40.0%), and comorbidities (n = 9; 15.0%). After adjusting for relevant variables, predictors of non-adherence included older age at diagnosis (OR 1.02, 95% CI 1.00-1.04), colorectal cancer (OR 3.84, 95% CI 1.99-7.42), higher ECOG status (OR 1.59, 95% CI 1.18-2.16), and a more recent MTB conference (OR 1.20, 95% CI 1.03-1.41).</p><p><strong>Conclusion: </strong>Overall, guideline adherence was high for colorectal and breast cancer and comparable to results from academic medical centers. However, results need to be confirmed in other tumor entities.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"4"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma.","authors":"Francesca Huwyler, Roland Giger, Ruben Bill, Daniel Rauch, Simon Haefliger","doi":"10.1007/s00432-024-06044-2","DOIUrl":"10.1007/s00432-024-06044-2","url":null,"abstract":"<p><strong>Purpose: </strong>Induction chemotherapy (IC) for patients with locally advanced stage Head and Neck Squamous Cell Carcinomas (HNSCC) before radio-chemotherapy (RCT) or surgery remains a potential treatment option. This study analyzed how the response to IC correlates with survival outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective single-center study at a tertiary cancer center. Tumors were categorized by anatomical site and response to IC (non-responders vs. responders). Data were analyzed using Kaplan-Meier survival curves and Cox regression analysis.</p><p><strong>Results: </strong>A total of 48 patients received IC. Of these, 33 patients were radiologically evaluable for response. The majority of evaluable patients received either TPF (Docetaxel, Cisplatin, 5-Fluorouracil) (58%) or TP (Docetaxel, Cisplatin) (24%) as their IC regimen. Tumor reduction of 30% or more was observed in 23 patients (69.7%), the tumor control rate was 97%. The 2-year event-free survival (EFS) in the IC evaluable population was 53.1%, overall survival (OS) was 63.6%, and recurrence-free survival (RFS) was 62.5%. Patients with laryngeal or hypopharyngeal tumors that did not respond to IC had a significantly poorer prognosis. This effect was not statistically significant in tumors of the oral cavity or oropharynx, where it was only observed as a trend.</p><p><strong>Conclusion: </strong>IC is highly effective in treating locally advanced stage HNSCC. The response to IC is prognostic for survival, particularly in cancers of the larynx and hypopharynx.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"2"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of setup errors on dose distribution in cervical cancer radiotherapy and the margin from CTV to PTV.","authors":"Zhenghuan Li, Yuan Cheng, Jie Dong, Liwan Han, Luxi Chen, Shen Huang, Meifang Zhang, Manya Wu, Fantu Kong, Huamei Yan","doi":"10.1007/s00432-024-06032-6","DOIUrl":"10.1007/s00432-024-06032-6","url":null,"abstract":"<p><strong>Purpose: </strong>This study calculates the needed margin from clinical target volume (CTV) to planning target volume (PTV) in IMRT for cervical cancer. It also assesses the impact of setup errors on target and organ at risk (OAR) dose distribution.</p><p><strong>Methods: </strong>We retrospectively analyzed 50 cervical cancer patients who underwent IMRT, with 210 CBCT scans. We calculated the CTV-to-PTV margin and simulated setup errors in the TPS to reassess dose distribution impacts on targets and OAR.</p><p><strong>Results: </strong>Setup errors in X(anterior-posterior,AP), Y(cranial-caudal,CC), and Z(left-right,LR) directions were (1.4 ± 1.0) mm, (2.3 ± 1.5) mm, and (1.9 ± 1.2) mm, respectively, leading to CTV-to-PTV margins of 4.4 mm, 6.4 mm, and 5.8 mm. X-axis errors did not significantly affect target dosimetry (P > 0.05), but Y and Z errors did (P < 0.05). X-axis errors impacted the small intestine and rectum (P < 0.05), Y-axis errors mainly affected the colon (P < 0.05), and Z-axis errors affected the colon, small intestine, and rectum (P < 0.05).</p><p><strong>Conclusion: </strong>Our study underscores the need to account for setup errors in radiotherapy for cervical cancer. Customizing the CTV-to-PTV margin based on institutional error data is key to maintaining target dose coverage and optimizing treatment outcomes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"516"},"PeriodicalIF":2.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization.","authors":"Alexey Surov, Andreas Wienke, Jan Borggrefe, Timo Alexander Auer, Bernhard Gebauer, Aline Mähringer-Kunz, Felix Nensa, Johannes Haubold, Benedikt Michael Schaarschmidt, René Hosch, Jens Kleesiek, Thierno D Diallo, Natascha Roehlen, Dominik Bettinger, Michel Eisenblätter, Verena Steinle, Philipp Mayer, David Zopfs, Daniel Pinto Dos Santos, Lukas Müller, Roman Kloeckner","doi":"10.1007/s00432-024-06043-3","DOIUrl":"10.1007/s00432-024-06043-3","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of the present study was to analyze associations between different skeletal muscle quality parameters and survival in patients with hepatocellular carcinoma (HCC) undergoing treatment with transarterial chemoembolization (TACE).</p><p><strong>Methods: </strong>We retrospectively enrolled 784 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. Intramuscular adipose tissue (IMAT) and skeletal muscle density (SMD) were estimated. Myosteatosis was defined as SMD < 28.0 HU for men and < 23.8 HU for women. Furthermore, albumin-SMD score (ADS) was calculated as follows: serum albumin (g/dL) × SMD (HU). To assess the impact of muscle quality on survival, Cox regression model was used. Kaplan-Meier curves were used for survival analysis. Parameters of skeletal muscle quality were compared in univariate and multivariate regression analyses, adjusted for established risk factors.</p><p><strong>Results: </strong>In the overall sample, survivors had higher SMD and ADS in comparison to non-survivors. Patients with low ADS had a lower OS than patients with high ADS (8.4 vs. 14.3 months, p < 0.001). In alcohol-induced HCC, none of the analyzed parameters of muscle quality influenced survival. In viral induced HCC, patients with low ADS had lower OS than patients with high ADS (8.8 vs. 15.7 months, p < 0.001). In patients with non-alcoholic steatohepatitis (NASH), none of the analyzed parameters of muscle quality influenced survival.</p><p><strong>Conclusions: </strong>Low ADS is an independent predictor of worse OS in patients with viral-induced HCC undergoing treatment with TACE. In alcohol-induced and NASH-induced HCCs, parameters of muscle quality do not influence OS.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"515"},"PeriodicalIF":2.7,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centres.","authors":"Franziska Neemann, Lina Jansen, Silke Hermann, Christian Silcher, Madelaine Hettler, Peter Hohenberger, Dario Callegaro, Alessandro Gronchi, Marco Fiore, Rosalba Miceli, Frits Van Coevorden, Winan Van Houdt, Sylvie Bonvalot, Piotr Rutkowski, Jacek Skoczylas, Carol J Swallow, Rebecca Gladdy, Dirk C Strauss, Andrew Hayes, Mark Fairweather, Chandrajit P Raut, Jens Jakob","doi":"10.1007/s00432-024-06033-5","DOIUrl":"10.1007/s00432-024-06033-5","url":null,"abstract":"<p><strong>Purpose: </strong>Retroperitoneal sarcomas (RPS) are rare, heterogeneous tumours. Treatment recommendations are mainly derived from cohorts treated at reference centres. The applicability of data from cancer registries (CR) is controversial. This work compares CR and TARPSWG (Transatlantic Australasian Retroperitoneal Sarcoma Working Group) data to assess the representativeness of the TARPSWG and the applicability of the CR data.</p><p><strong>Methods: </strong>TARPSWG cohort has previously been described. The CR Baden-Württemberg cohort includes patients with primary RPS M0 (years 2016-2021, ICD-10 C.49.4/5, C48.x) who underwent surgery within 12 months. Only patients with sarcoma-typical histology codes as used for the German Cancer Society certification system were included. Patient, tumour and therapy factors as well as survival times were compared with Chi²-test, Kaplan Meier curves, and adjusted models.</p><p><strong>Results: </strong>1000 (TARPSWG) and 364 (CR) patients were included. CR patients were older (median: 64 years vs. 58 years), had more high-grade tumours (FNCLCC 3 48.1% vs. 27.4%, p < 0.0001) and the 5-year survival rate was significantly lower (56.3% vs. 67.9%, p = 0.0015). The proportions of dedifferentiated liposarcoma (CR 37.1% vs. 37.0%) and leiomyosarcoma (CR 20.1% vs. 19.2%), and patterns of recurrence in these most frequent RPS subtypes were similar.</p><p><strong>Conclusion: </strong>ICD-O/ICD 10 based filters appear to be a valid tool for extracting RPS cases from CR. The similar distribution and biological behavior of distinct RPS subtypes suggests that TARPS-WG are representative, and CR data may be used to verify recommendations derived from reference centre cohorts. Complementary use of data from different sources warrants further investigation in rare cancers.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"514"},"PeriodicalIF":2.7,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zinc oxide nanoparticles mitigate the malignant progression of ovarian cancer by mediating autophagy-dependent ferroptosis.","authors":"Wenli Gu, Caihong Yang","doi":"10.1007/s00432-024-06029-1","DOIUrl":"10.1007/s00432-024-06029-1","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have shown that ZnO-NPs induce autophagy and inhibit the malignant progression of ovarian cancer (OC) cells. This study aims to further explore the mechanism of action of ZnO-NPs on OC.</p><p><strong>Methods: </strong>SKOV3 cells were treat with different concentrations of ZnO-NPs and cell proliferation was assessed through EDU staining. A Xenograft tumor model was established and mice were treated with varying doses of ZnO-NPs for 21 days. Tumor volume and the weight of each group of mice were measured, and the expression of KI67 in tumor tissues was analyzed to evaluate tumor proliferation in vivo. The expression of autophagy and ferroptosis-related proteins in cells and tumor tissues was examined through immunofluorescence, ELISA, and western blotting assays. The relationship between ZnO-NPs induced autophagy and ferroptosis was further investigated using the ferroptosis inhibitors Fer-1, autophagy inhibitor 3-MA and siRNA for ATG5 (si-ATG5).</p><p><strong>Results: </strong>ZnO-NPs dose-dependently reduced the proliferation of SKOV3 cells in vitro. In vivo, both high and low doses of ZnO-NPs effectively inhibited the growth of tumor, reduced pathological damage and the expression of KI67 in tumor tissues. Additionally, ZnO-NPs increased the levels of iron, MDA, 4-HNE, oxidized lipid ROS, ATG5, TFR1, ACSL4, LC3, and Beclin1 in cells and tumor tissues, decreased the expression of SOD, GSH-Px, non-oxidized lipid ROS, GPX4, and p62. Transfection with si-ATG5 or treatment with 3-MA significantly weakened these effects of ZnO-NPs in vitro, with si-ATG5 having a stronger weakening effect on the action of ZnO-NPs than 3-MA. However, ferroptosis inhibitor has a lesser impact on the autophagy of ZnO-NPs-treated SKOV3 cells than the effect of autophagy inhibitors and si-ATG5 on the ferroptosis of ZnO-NPs-treated SKOV3 cells.</p><p><strong>Conclusion: </strong>ZnO-NPs inhibited the malignant progression of SKOV3 cells by inducing autophagy-dependent ferroptosis.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"513"},"PeriodicalIF":2.7,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}